Glucagon-Like Peptide-1 Protects Against Cardiac Microvascular Injury in Diabetes via a cAMP/PKA/Rho-Dependent Mechanism
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Impaired cardiac microvascular function contributes to cardiovascular complications in diabetes. Glucagon-like peptide-1 (GLP-1) exhibits potential cardioprotective properties in addition to its glucose-lowering effect. This study was designed to evaluate the impact of GLP-1 on cardiac microvascular injury in diabetes and the underlying mechanism involved. Experimental diabetes was induced using streptozotocin in rats. Cohorts of diabetic rats received a 12-week treatment of vildagliptin (dipeptidyl peptidase-4 inhibitor) or exenatide (GLP-1 analog). Experimental diabetes attenuated cardiac function, glucose uptake, and microvascular barrier function, which were significantly improved by vildagliptin or exenatide treatment. Cardiac microvascular endothelial cells (CMECs) were isolated and cultured in normal or high glucose medium with or without GLP-1. GLP-1 decreased high-glucose–induced reactive oxygen species production and apoptotic index, as well as the levels of NADPH oxidase such as p47phox and gp91phox. Furthermore, cAMP/PKA (cAMP-dependent protein kinase activity) was increased and Rho-expression was decreased in high-glucose–induced CMECs after GLP-1 treatment. In conclusion, GLP-1 could protect the cardiac microvessels against oxidative stress, apoptosis, and the resultant microvascular barrier dysfunction in diabetes, which may contribute to the improvement of cardiac function and cardiac glucose metabolism in diabetes. The protective effects of GLP-1 are dependent on downstream inhibition of Rho through a cAMP/PKA-mediated pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [444]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“GLP-1 receptor (GLP-1R) is widely expressed in islet cells, kidney, lung, brain, and, interestingly, heart (6,7).”
BackgroundCoronary Microvascular Dysfunction
Camici, P. G., & Crea, F. (2007) · New England Journal of Medicine · doi:10.1056/nejmra061889 · Cited by 1,605
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428 · cited 1×
“Accumulating evidence has demonstrated that microvascular injury plays a very important role in the diabetic cardiovascular dysfunction (4,5).”
BackgroundCoronary Microvascular Dysfunction
Crea, F., Lanza, G. A., & Camici, P. G. (2014) · Springer eBooks · doi:10.1007/978-88-470-5367-0 · Cited by 1,287
The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism
Koo, S.-H., Flechner, L., Qi, L., Zhang, X., Screaton, R. A., Jeffries, S., Hedrick, S., Xu, W., Boussouar, F., Brindle, P., et al. (2005) · Nature · doi:10.1038/nature03967 · Cited by 995 · cited 1×
“Complete viral vectors were generated by homologous recombination with the AdEASY vector as described (27).”
MethodNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 1×
“Furthermore, a study of diabetic patients found that infusion of GLP-1 was associated with improved endothelial function (9).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638 · cited 1×
“For example, GLP-1 is capable of protecting the heart against ischemia/reperfusion injury (38).”
BackgroundThe Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion
MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590 · cited 5×
“To assess the potential role of intact GLP-1, DPP-4 inhibitors such as vildagliptin and GLP-1 analog exenatide are used as a means of preventing its degradation.”
BackgroundInfluentialExenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H. E., Kim, W. Y., Mathiasen, A. B., Jørgensen, E., Helqvist, S., Saunamäki, K., Clemmensen, P., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr309 · Cited by 550 · cited 1×
“It has been shown that administration of GLP-1 at the time of reperfusion was effective in decreasing myocardial infarct size in patients with acute myocardial infarction (8).”
BackgroundArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy
An, D., & Rodrigues, B. (2006) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00278.2006 · Cited by 446 · cited 1×
“The increased rate of endothelial apoptosis in diabetes may contribute to microvascular barrier dysfunction and rarefaction, which lead to myocardial metabolism abnormalities and impaired intracellular calcium homeostasis (44).”
BackgroundSpector, K. S. (1998) · Clinical Cardiology · doi:10.1002/clc.4960211205 · Cited by 443 · cited 1×
“Diabetic cardiovascular disease results from many causes such as microangiopathy, myocardial metabolic abnormalities, and fibrosis (2,3).”
BackgroundFolli, F., Corradi, D., Fanti, P., Davalli, A., Paez, A., Giaccari, A., Perego, C., & Muscogiuri, G. (2011) · Current Diabetes Reviews · doi:10.2174/157339911797415585 · Cited by 376 · cited 1×
“It is well-known that diabetes and hyperglycemia could increase intracellular reactive oxygen species (ROS), subsequently inducing apoptotic cell death, inflammation, and injury in endothelial cells (12,13).”
BackgroundOeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267 · cited 1×
“DPP-4 inhibition was found to protect against vascular senescence, which was attenuated by GLP-1 in a receptor-dependent manner involving downstream PKA signaling (49).”
BackgroundInsulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
Parkes, D. G., Pittner, R., Jodka, C., Smith, P., & Young, A. (2001) · Metabolism · doi:10.1053/meta.2001.22519 · Cited by 241 · cited 1×
“It has been reported that GLP-1 is an intestinally derived hormone acting in vivo to promote the level of circulating insulin, leading to reduced blood glucose levels (36).”
BackgroundNeschen, S., Morino, K., Dong, J., Wang-Fischer, Y., Cline, G. W., Romanelli, A. J., Rossbacher, J. C., Moore, I. K., Regittnig, W., Munoz, D. S., et al. (2007) · Diabetes · doi:10.2337/db06-1206 · Cited by 233
Dicker, D. (2011) · Diabetes Care · doi:10.2337/dc11-s229 · Cited by 229
Burger, D., Montezano, A. C., Nishigaki, N., He, Y., Carter, A., & Touyz, R. M. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.222703 · Cited by 220 · cited 1×
“(47) reported an important role of Rho/ROCK in angiotensin II–induced upregulation of endothelial NADPH oxidase and subsequently increased endothelial superoxide production.”
BackgroundEfficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Voulgari, Tentolouris, N., & Papadogiannis, D. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s11681 · Cited by 210
Does microvascular disease predict macrovascular events in type 2 diabetes?
Rosenson, R. S., Fioretto, P., & Dodson, P. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.029 · Cited by 161 · cited 1×
“There is convincing evidence suggesting that endothelial apoptosis occurs at an earlier time point compared with pathological changes in cardiomyocytes in diabetes (43).”
BackgroundIncretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 153
Endothelial dysfunction in type 2 diabetes mellitus
Avogaro, A., Fadini, G. P., Gallo, A., Pagnin, E., & de Kreutzenberg, S. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.015 · Cited by 148
Rolfe, B. E., Worth, N. F., WORLD, C., Campbell, J. H., & CAMPBELL, G. R. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.04.023 · Cited by 134 · cited 1×
“Rho is a key regulator for oxidative stress (30).”
BackgroundCellular Dysfunction in Diabetes as Maladaptive Response to Mitochondrial Oxidative Stress
Naudi, A., Jove, M., Ayala, V., Cassanye, A., Serrano, J., Gonzalo, H., Boada, J., Prat, J., Portero-Otin, M., & Pamplona, R. (2012) · Experimental Diabetes Research · doi:10.1155/2012/696215 · Cited by 129 · cited 1×
“It is well-known that diabetes and hyperglycemia could increase intracellular reactive oxygen species (ROS), subsequently inducing apoptotic cell death, inflammation, and injury in endothelial cells (12,13).”
BackgroundHyun Lee, C., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 118 · cited 1×
“GLP-1 receptor (GLP-1R) is widely expressed in islet cells, kidney, lung, brain, and, interestingly, heart (6,7).”
BackgroundRoles of Rho-Associated Kinase and Oxidative Stress in the Pathogenesis of Aortic Stiffness
Noma, K., Goto, C., Nishioka, K., Jitsuiki, D., Umemura, T., Ueda, K., Kimura, M., Nakagawa, K., Oshima, T., Chayama, K., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.082 · Cited by 101 · cited 1×
“Recent evidence demonstrates that Rho plays a regulatory role in oxidative stress in many diseases (15,16).”
BackgroundMazzone, T. (2010) · Circulation · doi:10.1161/circulationaha.109.913350 · Cited by 83 · cited 1×
“Diabetes is recognized as a major risk factor for cardiovascular disease, the leading cause for morbidity and mortality in the diabetic population (1).”
Background(2010) · The Lancet · doi:10.1016/s0140-6736(10)61995-2 · Cited by 81
Brown, J. A., Diggs‐Andrews, K. A., Gianino, S. M., & Gutmann, D. H. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.08.008 · Cited by 75
Schuhmacher, S., Wenzel, P., Schulz, E., Oelze, M. W., Mang, C. F., Kamuf, J., Gori, T., Jansen, T., Knorr, M., Karbach, S. H., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.149542 · Cited by 70 · cited 1×
“ROS production, an index of oxidative stress, in viable CMECs was measured by lucigenin-enhanced chemiluminescence assay under adaptation of the previously described method (25).”
MethodVergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58 · cited 1×
“In addition to its glucose-lowering property, GLP-1 also exhibits potential cardioprotective properties (37).”
BackgroundZuo, L., Youtz, D. J., & Wold, L. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023116 · Cited by 53 · cited 1×
“oxidative fluorescent microtopography, as described recently (26).”
Rodríguez, A., Becerril, S., Valentí, V., Moncada, R., Méndez-Giménez, L., Ramírez, B., Lancha, A., Martín, M., Burrell, M. A., Catalán, V., et al. (2012) · Obesity Surgery · doi:10.1007/s11695-012-0702-4 · Cited by 52
Xiao, Y.-F., Nikolskaya, A., Jaye, D. A., & Sigg, D. C. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-6 · Cited by 47 · cited 1×
“(48) demonstrated that GLP-1 promoted voltagegated L-type Ca current in the heart possibly through a cAMP/PKA-dependent pathway and may contribute, in part, to prolonged action potential duration.”
BackgroundAcute blood–brain barrier permeabilization in rats after systemic Phoneutria nigriventer venom
Rapôso, C., Zago, G. M., da Silva, G. H., & Höfling, M. A. D. C. (2007) · Brain Research · doi:10.1016/j.brainres.2007.02.086 · Cited by 44 · cited 1×
“Lanthanum nitrate has been widely used to assess the barrier function of endothelial cells (29).”
BackgroundRho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats
Ma, Z., Zhang, J., Ji, E., Cao, G., Li, G., & Chu, L. (2011) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2011.05561.x · Cited by 40 · cited 1×
“Recent evidence demonstrates that Rho plays a regulatory role in oxidative stress in many diseases (15,16).”
BackgroundEguchi, M., Kim, Y. H., Kang, K. W., Shim, C. Y., Jang, Y., Dorval, T., Kim, K. J., & Sweeney, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030450 · Cited by 39 · cited 1×
“CT scanner (Mediso Nano PET/CT) described previously (21).”
MethodWei, L., Sun, D., Yin, Z., Yuan, Y., Hwang, A., Zhang, Y., Si, R., Zhang, R., Guo, W., Cao, F., et al. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0439-2 · Cited by 36
Self-citationAcar, E., Ural, D., Bildirici, U., Şahı̇n, T., & Yılmaz, İ. (2011) · The Anatolian Journal of Cardiology · doi:10.5152/akd.2011.196 · Cited by 36
A PKC-β inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats
Wei, L., Yin, Z., Yuan, Y., Hwang, A., Lee, A. S., Sun, D., Li, F., Di, C., Zhang, R., Cao, F., et al. (2010) · Microvascular Research · doi:10.1016/j.mvr.2010.01.003 · Cited by 34
Self-citationHao, M., Li, S., Sun, C., Jingyu-Xu, Lin, Y., Liu, K., Wang, L., Chuan-xun, L., Zhou, Q., Du, J., et al. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.030 · Cited by 32 · cited 1×
“Accumulating evidence has demonstrated that microvascular injury plays a very important role in the diabetic cardiovascular dysfunction (4,5).”
BackgroundHuang, X., Zhang, J., Liu, J., Sun, L., Zhao, H., Lu, Y., Wang, J., & Li, J. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23415 · Cited by 29 · cited 1×
“NADPH oxidase is the most important enzyme responsible for superoxide production in vasculature (14).”
BackgroundWang, D., Wang, H., Luo, P., Hwang, A., Sun, D., Wang, Y., Zhang, Z., Liu, N., Wang, S., Li, C., et al. (2012) · Cell Biology International · doi:10.1042/cbi20110235 · Cited by 28 · cited 1×
“CMECs were isolated as previously described, with minor modifications (24).”
MethodSelf-citationCurrent Concepts in Diabetic Microvascular Dysfunction
Fontaine, J. L., Harkless, L. B., Davis, C. E., Allen, M. A., & Shireman, P. K. (2006) · Journal of the American Podiatric Medical Association · doi:10.7547/0960245 · Cited by 22 · cited 1×
“Impaired cardiac microvascular function is thought to contribute greatly to diabetic cardiovascular disease (41,42).”
BackgroundTakeshima, H., Kobayashi, N., Koguchi, W., Ishikawa, M., Sugiyama, F., & Ishimitsu, T. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.11114 · Cited by 18 · cited 1×
“Inhibition of Rho may result in the cardioprotective effect on cardiovascular remodeling associated with oxidative stress (17).”
BackgroundSullivan, S. D., Alfonso‐Cristancho, R., Conner, C., Hammer, M., & Blonde, L. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.11.1280 · Cited by 15 · cited 1×
“In this study, GLP-1 was found to improve cardiac function and glucose metabolism in hearts from diabetic rats, consistent with a recent clinical report in which GLP1–based therapy reduces overall cardiovascular events in diabetic patients (40).”
ResultBevis, D. (2011) · InTech eBooks · doi:10.5772/22332 · Cited by 13
Shen, M., Sun, D., Li, W., Liu, B., Wang, S., Zhang, Z., & Cao, F. (2012) · Experimental Diabetes Research · doi:10.1155/2012/146194 · Cited by 12
Self-citationPeterson, G. M. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.653392 · Cited by 11
Angioarchitecture of the ventral surface of the tongue from Wistar rats
Verli, F. D., Marinho, S. A., Rossi‐Schneider, T. R., Yurgel, L. S., & de Souza, M. A. L. (2008) · Scanning · doi:10.1002/sca.20122 · Cited by 11 · cited 1×
“Scanning electron microscopy was used to evaluate cardiac microvascular integrity (28).”
MethodBody distribution of 11C-methionine and 18FDG in rat measured by microPET
Štolc, S., Jakubíková, L., & Kukurová, I. J. (2011) · Interdisciplinary Toxicology · doi:10.2478/v10102-011-0010-1 · Cited by 10
Chen, W., Zhou, Y., Zhang, H., Qian, H., Huang, W., Yang, B., Han, J., Zhou, J., Chi, Y., & Ni, S. (2012) · Protein and Peptide Letters · doi:10.2174/092986612799080194 · Cited by 5 · cited 5×
“To assess the potential role of intact GLP-1, DPP-4 inhibitors such as vildagliptin and GLP-1 analog exenatide are used as a means of preventing its degradation.”
BackgroundInfluential
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“443 These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid pro fi les, 444 preserving endothelial integrity and regulating endothelial function, 445 as well as modulating in fl ammatory processes.”
BackgroundMacro‐ and microvascular endothelial dysfunction in diabetes: 糖尿病诱导的内皮细胞功能损伤
Shi, Y., & Vanhoutte, P. M. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12521 · Cited by 545
Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550
“Our previous study identified Nox4 as a source for intracellular ROS overproduction [41].”
BackgroundSelf-citationYang, D.-R., Wang, M.-Y., Zhang, C.-L., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1359255 · Cited by 280
Self-citationRegulation of Glucose Homeostasis by GLP-1
Nadkarni, P., Chepurny, O. G., & Holz, G. G. (2014) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-800101-1.00002-8 · Cited by 287
Metadata
- Authors
- Wang, D., Luo, P., Wang, Y., Li, W., Wang, C., Sun, D., Zhang, R., Su, T., Ma, X., Zeng, C., Wang, H., Ren, J., & Cao, F.
- Affiliations
- Xijing Hospital (CN)
- University of Wyoming (US)
- Corresponding author
- Cao, Feng
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 1697-1708
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3636622
- OpenAlex
- W2117213923
- Cited by
- 179
- References
- 54
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 12 · 2023: 6 · 2022: 13 · 2021: 11 · 2020: 11 · 2019: 15 · 2018: 9 · 2017: 21 · 2016: 16 · 2015: 21 · 2014: 22 · 2013: 7
- FWCI
- 17.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- glucagon-like peptide-1, vildagliptin, exenatide, DPP-4 inhibitors, cardiac microvascular endothelial cells, cAMP/PKA signaling, Rho, oxidative stress, apoptosis, NADPH oxidase, cardiac glucose metabolism, streptozotocin-induced diabetes
- MeSH terms
- Exenatide, Cyclic AMP, Animals, Cardiotonic Agents, Cells, Cultured, Diabetic Angiopathies, Disease Models, Animal, Endothelium, Vascular, Heart Ventricles, Hyperglycemia, Hypoglycemic Agents, Male, Peptides, Random Allocation, Venoms, Second Messenger Systems, Rats, Sprague-Dawley, Oxidative Stress, rho GTP-Binding Proteins, Rats, Glucagon-Like Peptide 1, AMP-Activated Protein Kinases, Microvessels, Diabetic Cardiomyopathies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.